Article Text

PDF
Fingolimod in multiple sclerosis: profile of use in habitual practice
  1. Noelia Fernández Bargiela,
  2. Cristina Mondelo García,
  3. Víctor Giménez Arufe,
  4. José Ramón Vizoso Hermida,
  5. Isabel Martín Herranz
  1. Pharmacy Service, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade da Coruña (UDC), A Coruña, Spain
  1. Correspondence to Dr Noelia Fernández Bargiela, Service of Pharmacy, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña 15006, Spain; noelia.fernandez.bargiela{at}sergas.es

Abstract

Objectives Fingolimod is the first oral drug indicated in monotherapy as a modifier of the course of very active relapsing-remitting multiple sclerosis (RRMS). The safety profile of fingolimod is well established in clinical trials and post-marketing studies. Our objective was to study the profile of fingolimod use in our health area.

Methods A retrospective, observational, descriptive study was performed on the use of fingolimod in adult patients diagnosed with RRMS between January 2015 and February 2017 or until suspension of treatment in a reference hospital in north-western Spain.

Results A total of 55 patients were included with a mean±SD time of treatment with fingolimod of 26±14.6 months (range 2–53). Thirteen patients permanently discontinued the treatment (10 due to outbreaks/disease progression and 3 due to adverse effects). No statistically significant differences were found between the percentage of patients who discontinued fingolimod and who had received only one previous treatment and those who had received two or more treatments. No cases of symptomatic bradycardia were reported.

Conclusions Fingolimod is a safe treatment for patients with multiple sclerosis.

  • fingolimod
  • tolerability
  • relapsing-remitting multiple sclerosis
  • disease modifying agents
  • clinical practice
  • adverse effects

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.